Arginine vasopressin antagonism - New treatment option in chronic heart failure;Vasopressinantagonisme - Nytt behandlingsprinsipp ved hjertesvikt

Tidsskrift for den Norske Laegeforening

Volumn 127, Issue 2, 2007, Pages 179-182

  Solberg, Ole Geir ^a,b   Omland, Torbjørn ^a  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGIPRESSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; VASOPRESSIN ANTAGONIST;

DATA BASE; DRUG EFFECT; DRUG INHIBITION; HEART FAILURE; HEMODYNAMICS; HOSPITALIZATION; HUMAN; MEDICAL LITERATURE; MORTALITY; PROGNOSIS; REVIEW;

ANIMALS; ANTIDIURETIC AGENTS; ARGININE VASOPRESSIN; AZEPINES; BENZAMIDES; BENZAZEPINES; HEART FAILURE, CONGESTIVE; HUMANS; NEPHRONS; PROGNOSIS; RECEPTORS, VASOPRESSIN; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 33846439767     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Cowie MR, Mosterd A, Wood DA et al. The epidemiology of heart failure. Eur Heart J 1997; 18: 208-25.
2. McKee PA, Castelli WP, McNamara PM et al. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971; 285: 1441-6.
3. Cowie MR, Wood DA, Coats AJS et al. Incidenc and etiology of heart failure. Eur Heart J 1999; 20: 421-8.
4. Cleland JGF, Gemmel I, Khand A et al. Is the prognosis of heart failure improving? Eur J Heart Fail 1999; 1: 229-41.
5. Ishikawa SE, Schrier RW. Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion. Clin Endocrinol 2003; 58: 1-17.
6. Sanghi P, Uretsky BF, Schwarz ER. Vasopressin antagonism: a future treatment option in heart failure. Eur Heart J 2005; 26: 538-43.
7. Gullestad L, Aukrust P. Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. Am J Cardiol 2005; 95: 17C-23C.
8. Chikanza IC, Grossman AS. Hypothalamic-pituitary-mediated immuno-modulation: arginine vasopressin is a neuroendocrine immune mediator. Br J Rheumatol 1998; 37: 131-6.
9. Lee CR, Watkins ML, Patterson JH et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J 2003; 146: 9-18.
10. Abel A, Wittau N, Wieland T et al. Cell cycle-dependent coupling of the vasopressin V1a receptor to different G proteins. J Biol Chem 2000; 275: 32543-51.
11. Thibonnier M, Auzan C, Madhun Z et al. Molecular cloning, sequencing and functional expression of a cDNA encoding the human V1a vasopressin receptor. J Biol Chem 1994; 269: 3304-10.
12. Nielsen S, Kwon TH, Christensen BM et al. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 1999; 10: 647-63.
13. Burrell LM, Phillips PA, Stephenson JM et al. Vasopressin and a nonpeptide antidiuretic hormone receptor antagonist (OPC-31260). Blood Press 1994; 3: 137-41.
14. Xu DL, Martin PY, Ohara M et al. Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. J Clin Invest 1997; 99: 1500-5.
15. Francis GS, Goldsmith SR, Levine BT et al. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984; 101: 370-7.
16. Francis GS, Benedict C, Johnstone DE et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82: 1724-9.
17. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341: 577-85.
18. Naitoh M, Suzuki H, Murakami M et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol. 1994; 267: H2245-54.
19. Yamamura Y, Ogawa H, Yamashita H et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 1992; 105: 787-91.
20. Rouleau JL, Packer M, Moye L et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994; 24: 583-91.
21. Nakamura Y, Haneda T, Osaki J et al. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V1A receptor. Eur J Pharmacol 2000; 391: 39-48.
22. Chin MH, Goldman L. Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. Arch Intern Med 1996 Sep 9; 156: 1814-20.
23. Goldsmith SR, Francis GS, Cowley AW jr. et al. Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J Am Coll Cardiol 1986; 8: 779-83.
24. Burrell LM, Phillips PA, Rolls KA et al. Vascular responses to vasopressin antagonists in man and rat. Clin Sci (Lond) 1994; 87: 389-95.
25. Yamamura Y, Ogawa H, Chihara T et al. OPC-21268, an orally effective, non peptide vasopressin V1 receptor antagonist. Science 1991; 252: 572-4.
26. 2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001; 104: 2417-23.
27. Russell SD, Selaru P, Pyne DA et al. Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial. Am Heart J 2003; 145: 179-86.
28. 2 antagonist in men. J Pharmacol Exp Ther 1995; 272: 546-51. Erratum: J Pharmacol Exp Ther 1995; 274: 1573.
29. Gerbes AL, Gulberg V, Gines P et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003; 124: 933-9.
30. Wong F, Blei AT, Blendis LM et al. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentrationin patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003; 37: 182-91.
31. Abraham WT, Shamshirsaz AA, McFann K et al. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol 2006; 47: 1615-21.
32. 2-receptor blockade with tolvaptan in patients with chronic heart failure. Circulation 2003; 107: 2690-6.
33. Gheorghiade M, Gattis WA, O'Conner C et al. Effects of tolvaptan vasopressin antagonist, in patients hospitalized with worsening heart failure. JAMA 2004; 291: 1963-71.
34. Gheorghiade M, Gattis WA, Barbagelata A et al. Rationale and study design for a multicenter, randomized, double-blind, placebocontrolled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. Am Heart J 2003; 145: S51-S54.
35. De Luca L, Orlandi C, Udelson JE et al. Overview of vasopressin receptor antagonists in heart failure resulting in hospitalization. Am J Cardiol 2005; 96: 24L-33L.